Post by Ophthalmology Times

According to a new announcement, Dompé has dosed the first US patient in a phase 3 study of cenegermin-bkbj ophthalmic solution for the treatment of persistent corneal epithelial defect (PCED). The multicenter, randomized, double-masked trial—named Orunea—will compare cenegermin-bkbj against placebo in approximately 150 adult patients, with a primary endpoint of complete epithelial healing of the cornea https://hubs.li/Q04l3L_r0